Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Gain Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Gain Therapeutics, Inc.’s stock price such as:

• Gain Therapeutics, Inc.’s current stock price and volume
• Why Gain Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for GANX from analysts
• GANX’s stock price momentum as measured by its relative strength

About Gain Therapeutics, Inc. (GANX)

Before we jump into Gain Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company’s lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson’s disease with or without a GBA1 mutation. It has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher’s disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Want to learn more about Gain Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Gain Therapeutics, Inc..

Gain Therapeutics, Inc.’s Stock Price as of Market Close

As of April 17, 2026, 4:00 PM, CST, Gain Therapeutics, Inc.’s stock price was $2.130.

Gain Therapeutics, Inc. is up 3.9% from its previous closing price of $2.050.

During the last market session, Gain Therapeutics, Inc.’s stock traded between $2.060 and $2.200. Currently, there are approximately 37.82 million shares outstanding for Gain Therapeutics, Inc..

Gain Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Gain Therapeutics, Inc. Stock Price History

Gain Therapeutics, Inc.’s (GANX) price is currently up 9.79% so far this month.

During the month of April, Gain Therapeutics, Inc.’s stock price has reached a high of $2.200 and a low of $1.720.

Over the last year, Gain Therapeutics, Inc. has hit prices as high as $4.340 and as low as $1.410. Year to date, Gain Therapeutics, Inc.’s stock is down 33.85%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Gain Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 17, 2026, there were 0 analysts who downgraded Gain Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Gain Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Gain Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Gain Therapeutics, Inc. (GANX) by visiting AAII Stock Evaluator.

Relative Price Strength of Gain Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 17, 2026, Gain Therapeutics, Inc. has a weighted four-quarter relative price strength of 1.90%, which translates to a Momentum Score of 60 and is considered to be Average.

Want to learn more about how Gain Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Gain Therapeutics, Inc. Stock Price: Bottom Line

As of April 17, 2026, Gain Therapeutics, Inc.’s stock price is $2.130, which is up 3.9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Gain Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.